These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6798099)

  • 1. Development and characteristics of sucralfate.
    Nagashima R
    J Clin Gastroenterol; 1981; 3(Suppl 2):103-10. PubMed ID: 6798099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of peptic aggression by sucralfate. The view from the ulcer crater.
    Samloff IM
    Scand J Gastroenterol Suppl; 1983; 83():7-11. PubMed ID: 6415806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sucralfate, a basic aluminum salt of sucrose sulfate. IV. Interaction with enzyme pepsin.
    Yoshida N; Terao N; Nagashima R
    Arzneimittelforschung; 1980; 30(1):78-80. PubMed ID: 6768370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of sucralfate.
    Nagashima R
    J Clin Gastroenterol; 1981; 3(Suppl 2):117-27. PubMed ID: 6798100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sucralfate: development of a new concept of anti-ulcer treatment. Review of its pharmacodynamic properties].
    Gorget C
    Rev Med Interne; 1985 Jun; 6(3):313-9. PubMed ID: 3901171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of peptic activity by sucralfate.
    Samloff IM; O'Dell C
    Am J Med; 1985 Aug; 79(2C):15-8. PubMed ID: 3929601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sucralfate: antipeptic, antiulcer activities and antagonism of gastric emptying.
    Borella LE; Seethaler K; Lippmann W
    Arzneimittelforschung; 1979; 29(5):793-8. PubMed ID: 387045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sucralfate and its components on acid- and pepsin-induced damage to rat gastric epithelial cells.
    Furukawa O; Matsui H; Suzuki N
    Jpn J Pharmacol; 1997 Sep; 75(1):21-5. PubMed ID: 9334882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sucralfate protects the ulcer from acids and pepsin].
    von Bocko Polach U
    Med Klin; 1980 Oct; 75(21):764-7. PubMed ID: 6779100
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro and In vivo evaluations of a tableted antacid and sucralfate, a new antiulcer agent.
    McGraw BF; Hesterlee EJ; Lanza FL; Tesler MA
    Am J Gastroenterol; 1981 Nov; 76(5):412-5. PubMed ID: 6895973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adsorption of bile acids by sucralfate, antacids, and cholestyramine in vitro.
    Ståhlberg M; Jalovaara P; Laitinen S; Mokka R; Hentilä R; Järvensivu P; Kairaluoma M
    Clin Ther; 1987; 9(6):615-21. PubMed ID: 3440273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sucralfate (Ulcogant). The mechanism of action of a cytoprotective agent].
    Steiner KF
    Fortschr Med; 1983 Dec; 101(47-48):2197-200concl. PubMed ID: 6423500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sucralfate, a basic aluminum salt of sucrose sulfate. II. Inhibition of peptic hydrolysis as it results from sucrose sulfate interaction with protein substrate, serum albumins.
    Nagashima R; Yoshida N; Terao N
    Arzneimittelforschung; 1980; 30(1):73-6. PubMed ID: 6892774
    [No Abstract]   [Full Text] [Related]  

  • 14. Sucralfate prevents experimental peptic esophagitis in rabbits.
    Schweitzer EJ; Bass BL; Johnson LF; Harmon JW
    Gastroenterology; 1985 Mar; 88(3):611-9. PubMed ID: 3917956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1984 Mar; 27(3):194-209. PubMed ID: 6368184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate.
    Terao N; Yoshida N; Nagashima R
    Arzneimittelforschung; 1980; 30(1):76-8. PubMed ID: 6892775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of an antiulcer drug, sucralfate (a basic aluminum salt of sulfated disaccharide), on experimental gastric lesions and gastric secretion in rats.
    Okabe S; Takeuchi K; Kunimi H; Kanno M; Kawashima M
    Dig Dis Sci; 1983 Nov; 28(11):1034-42. PubMed ID: 6688779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology, clinical efficacy, and adverse effects of sucralfate, a nonsystemic agent for peptic ulcer.
    Spiro HM
    Pharmacotherapy; 1982; 2(2):67-71. PubMed ID: 6927335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective binding of sucralfate to ulcer lesion. II. Experiments in rats with gastric ulcer receiving 14C-sucralfate or potassium 14C-sucrose sulfate.
    Nagashima R; Hinohara Y; Hirano T; Tohira Y; Kamiyama H
    Arzneimittelforschung; 1980; 30(1):84-8. PubMed ID: 6892777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sucralfate (Ulcogant). Mechanism of action of a cytoprotective agent].
    Steiner KF
    Fortschr Med; 1983 Dec; 101(46):2153-6 contd. PubMed ID: 6689310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.